News Room

A collection of press releases, audio content and media clips featuring INFORMS members and their research.

On the left side of the graphic is a caucasian man wearing glasses and a suit. The photo shows him in portrait mode. The right side is blue and has a white logo and text.
News Release

Announcing the results of the 2026 INFORMS Board of Directors election and the new board for 2027.

Read More
A logo on white background
News Release

INFORMS has named 12 distinguished leaders as the 2026 class of INFORMS Fellows, one of the highest honors in the profession.

Read More
A human hand holds a magnifying glass up to a computer screen. The screen is out of focus but the area under the magnifying glass is crystal clear. It appears to be the website for the FDA.
News Release

Most medical devices do not hit the market through rigorous safety testing but by being deemed similar enough to something already approved—the “predicate” device through a mechanism known as the FDA’s 510(k) pathway. But similar is not a synonym for safe. While the assumption may be that substantial equivalence is a reasonable stand-in for a safety review, a share of devices cleared with this method still get recalled, and the FDA spends valuable time reviewing devices the same way, regardless of how risky it is on paper.

Read More

Resoundingly Human Podcast

An audio journey of how data and analytics save lives, save money and solve problems.

Media Contact

Jeff Cohen
Chief Strategy Officer
INFORMS
Catonsville, MD
[email protected]
443-757-3565

INFORMS in the News

What are you looking for?

Type of Content
Topic
Watch: A Stress Test for Supply Chains, Part 2

Watch: A Stress Test for Supply Chains, Part 2

Supply Chain Brain, April 19, 2021

David Simchi-Levi, professor of engineering systems at MIT, brings us up to date on the results of applying a supply-chain “stress test” to companies in multiple industries.

Johnson & Johnson COVID Vaccine Maker Emergent BioSolutions Asked To Stop Making Doses While FDA Investigation Underway

Johnson & Johnson COVID Vaccine Maker Emergent BioSolutions Asked To Stop Making Doses While FDA Investigation Underway

WJZ-TV 13, April 19, 2021

BALTIMORE (WJZ) — Emergent BioSolutions, the Baltimore, Maryland-based company manufacturing the Johnson & Johnson coronavirus vaccines, was asked to stop manufacturing COVID-19 related products, while the Food & Drug Administration continues its investigation into quality control issues at the plant that ruined 15 million potential doses of the vaccine.

Subject Matter Experts in

Supply Chain

View list of experts

Subject Matter Experts in

Healthcare

View list of experts

INFORMS Magazines

OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.

Access OR/MS Today Magazine

Analytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.

Access Analytics Magazine